A UCB employee’s personal LinkedIn profile described work on Phase 3 axial spondyloarthropathy for bimekizumab. The Panel ruled this promoted an unlicensed medicine and was not certified, breaching Clauses 3.1, 14.1 and 9.1.
Boehringer Ingelheim admitted that June 2019 MIMS carried a Spiolto Respimat full-page ad plus a double-sided bookmark insert, exceeding the two-page limit for a single product in a print journal.
An anonymous employee complained that Otsuka UK webpages listed POM brand/generic names and indications. The Panel ruled the pages promoted POMs to the public and were not access-restricted, breaching Clauses 26.1, 26.2, 28.1 and 9.1.
Following BBC criticism, the PMCPA assessed a Napp-sponsored New York meeting for UK pain specialists. The Panel found breaches relating to overseas venue justification and entertainment/hospitality, including Clause 2 discredit.
A GP challenged an Eliquis leavepiece claiming no dose adjustment in mild/moderate renal impairment. The PMCPA found the page misleading versus the SPC, upheld breaches including Clause 2, and rejected the Alliance’s appeal on standards/discredit.
